trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Taking the pneumococcal vaccine twice within two years is dangerous for older adults

the verdict
REFUTED
the evidence says no
Recorded sources
0 sources for · 3 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Evidence shows that taking pneumococcal vaccines or revaccinations within short or recommended intervals is safe for older adults, with only mild and self-limiting side effects, contradicting the claim that doing so is dangerous.

The analysis

The claim states that taking the pneumococcal vaccine twice within two years is dangerous for older adults. The retrieved literature (e.g., studies on PPSV23 revaccination and pneumococcal vaccine safety) consistently reports that pneumococcal revaccination and multi-dose schedules in older adults have a favorable safety profile with only mild, self-limiting adverse events, and no serious safety concerns. Therefore, the evidence refutes the claim of danger.

Evidence against · 3
Vaccination in Multiple Myeloma: Challenges and Strategies.
Recorded source metadata

Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Caserta S, Mendicino F, Morabito F, Gentile M. Vaccination in Multiple Myeloma: Challenges and Strategies.. 2025. https://doi.org/10.1111/ejh.70013

Studies on sequential pneumococcal administration and high-risk populations indicate that recommended multi-dose regimens are well-tolerated and clinically beneficial rather than dangerous.

See more details
More against · 2
Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60-70 years in Shanghai, China.
Recorded source metadata

Qiu J, Li Z, Huang F, Huang Z, Liang X, Li J, Liao Y, Guo X, Sun X. Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60-70 years in Shanghai, China.. 2025. https://doi.org/10.3389/fimmu.2025.1623611

Clinical safety data on elderly adults revaccinated with PPSV23 show that adverse events are mild, self-limiting, and have lower overall incidence rates compared to first-time vaccination.

IAPSM's Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India.
Recorded source metadata

Rao CR, Kamath VG, Nadda A, Parida SP, Sharma N, Goel K, Shetty RS, Verma M, Singh AK, Mishra A, Kiran S, Sankhe L, Gupta M. IAPSM's Position Paper on Pneumococcal Vaccine (PCV) for Adult Immunization in India.. 2024. https://doi.org/10.4103/ijcm.ijcm_739_24

Current guidelines for adult pneumococcal immunization note that the vaccines have minimal side effects and are well tolerated when administered according to schedule.

The paper trail · every fact has a biography
first checked02 Aug 2026
judged → REFUTED · 402 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.
trust me, bro: win the argument, pass the class, survive peer review.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt